MPV may reflect subcinical platelet activation in diabetic patients with and without diabetic retinopathy

Çıtırık, Mehmet; Beyazyıldız, Emrullah; Şimşek, Mert; Beyazyıldız, Özlem; Haznedaroglu, Ibrahim C.

doi:10.1038/eye.2014.298

Cited by 42 publications

(46 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These authors also found a 1.46-fold increase in the risk of PDR as MPV levels increased. On the other hand, Citirik et al 11 showed that MPV values did not change with DR stage, but there was a significant difference between the mean MPV values of diabetic patients and healthy subjects. In this study, we found a marked increase in MPV values in diabetic patients over healthy subjects; the increase in MPV values was more evident, particularly in patients with PDR.…”

Section: Discussionmentioning

confidence: 96%

“…Diabetic patients have increased MPV values compared with healthy individuals; at the same time, the risk of retinopathy development increases with higher MPV values in diabetic patients. 11,12 The purpose of this study was to evaluate the relation of the platelet indices MPV, PCT, PLT, and PDW of diabetic and control groups and to associate these indices with the stages of DR and DME. To the best of our knowledge, this study is the first to describe the relation between DME and platelet indices.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Mean Platelet Volume is Associated with Diabetic Macular Edema in Patients with Type-2 Diabetes Mellitus

Tetikoğlu

Aktaş

Sağdık

et al. 2016

Seminars in Ophthalmology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Introductionmentioning

confidence: 99%

Mean Platelet Volume is Associated with Diabetic Macular Edema in Patients with Type-2 Diabetes Mellitus

Tetikoğlu

Aktaş

Sağdık

et al. 2016

Seminars in Ophthalmology

View full text Add to dashboard Cite

show abstract

“…Aggregation was initiated by the addition of ADP solution (final concentration, 20 μM), thrombin (0.1 U/mL) and arachidonic acid (AA: 900 μM) in vivo (pre-treated with 400 mg/kg/d metformin, 50 μg/kg/d mtDNA or control buffer for 7 d) and in vitro (pre-incubated with 1 mM metformin, 40 ng/μL or control buffer for 6 h at 37 °C), and recorded for 5 min. In selected experiments platelets were pre-incubated for 0.5 h at 37 °C with neutralizing antibodies against DC-SIGN (120507; R&D Systems, USA, 25 μg/mL)4133495051.…”

Section: Methodsmentioning

confidence: 99%

Metformin Uniquely Prevents Thrombosis by Inhibiting Platelet Activation and mtDNA Release

Xin

Wei

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Thrombosis and its complications are the leading cause of death in patients with diabetes. Metformin, a first-line therapy for type 2 diabetes, is the only drug demonstrated to reduce cardiovascular complications in diabetic patients. However, whether metformin can effectively prevent thrombosis and its potential mechanism of action is unknown. Here we show, metformin prevents both venous and arterial thrombosis with no significant prolonged bleeding time by inhibiting platelet activation and extracellular mitochondrial DNA (mtDNA) release. Specifically, metformin inhibits mitochondrial complex I and thereby protects mitochondrial function, reduces activated platelet-induced mitochondrial hyperpolarization, reactive oxygen species overload and associated membrane damage. In mitochondrial function assays designed to detect amounts of extracellular mtDNA, we found that metformin prevents mtDNA release. This study also demonstrated that mtDNA induces platelet activation through a DC-SIGN dependent pathway. Metformin exemplifies a promising new class of antiplatelet agents that are highly effective at inhibiting platelet activation by decreasing the release of free mtDNA, which induces platelet activation in a DC-SIGN-dependent manner. This study has established a novel therapeutic strategy and molecular target for thrombotic diseases, especially for thrombotic complications of diabetes mellitus.

show abstract

“…Elevated MPV is an indicator of larger, more reactive platelets resulting from an increased platelet turnover. Recent studies revealed that MPV levels were positively correlated with platelet activation, and high MPV represented a risk factor for overall cardiovascular mortality [36-37]. In addition, the high MPV was also related to poor prognosis in non-cardiovascular disease critically ill patients [38].…”

Section: Discussionmentioning

confidence: 99%

Combination of Mean Platelet Volume/Platelet Count Ratio and the APACHE II Score Better Predicts the Short-Term Outcome in Patients with Acute Kidney Injury Receiving Continuous Renal Replacement Therapy

Sheng

et al. 2018

Kidney Blood Press Res

View full text Add to dashboard Cite

Background/Aims: Both the Acute physiology and Chronic Health Evaluation (APACHE II) score and mean platelet volume/platelet count Ratio (MPR) can independently predict adverse outcomes in critically ill patients. This study was aimed to investigate whether the combination of them could have a better performance in predicting prognosis of patients with acute kidney injury (AKI) who received continuous renal replacement therapy (CRRT). Methods: Two hundred twenty-three patients with AKI who underwent CRRT between January 2009 and December 2014 in a Chinese university hospital were enrolled. They were divided into survivals group and non-survivals group based on the situation at discharge. Receiver Operating Characteristic (ROC) curve was used for MPR and APACHE II score, and to determine the optimal cut-off value of MPR for in-hospital mortality. Factors associated with mortality were identified by univariate and multivariate logistic regression analysis. Results: The mean age of the patients was 61.4 years, and the overall in-hospital mortality was 48.4%. Acute cardiorenal syndrome (ACRS) was the most common cause of AKI. The optimal cut-off value of MPR for mortality was 0.099 with an area under the ROC curve (AUC) of 0.636. The AUC increased to 0.851 with the addition of the APACHE II score. The mortality of patients with of MPR > 0.099 was 56.4%, which was significantly higher than that of the control group with of ≤ 0.099 (39.6%, P= 0.012). Logistic regression analysis showed that average number of organ failure (OR = 2.372), APACHE II score (OR = 1.187), age (OR = 1.028) and vasopressors administration (OR = 38.130) were significantly associated with poor prognosis. Conclusion: Severity of illness was significantly associated with prognosis of patients with AKI. The combination of MPR and APACHE II score may be helpful in predicting the short-term outcome of AKI.

show abstract

MPV may reflect subcinical platelet activation in diabetic patients with and without diabetic retinopathy

Cited by 42 publications

References 21 publications

Mean Platelet Volume is Associated with Diabetic Macular Edema in Patients with Type-2 Diabetes Mellitus

Mean Platelet Volume is Associated with Diabetic Macular Edema in Patients with Type-2 Diabetes Mellitus

Metformin Uniquely Prevents Thrombosis by Inhibiting Platelet Activation and mtDNA Release

Combination of Mean Platelet Volume/Platelet Count Ratio and the APACHE II Score Better Predicts the Short-Term Outcome in Patients with Acute Kidney Injury Receiving Continuous Renal Replacement Therapy

Contact Info

Product

Resources

About